Title |
Clinical trials of CAR-T cells in China
|
---|---|
Published in |
Journal of Hematology & Oncology, October 2017
|
DOI | 10.1186/s13045-017-0535-7 |
Pubmed ID | |
Authors |
Bingshan Liu, Yongping Song, Delong Liu |
Abstract |
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 94 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 19 | 20% |
Researcher | 14 | 15% |
Student > Ph. D. Student | 11 | 12% |
Student > Master | 11 | 12% |
Other | 8 | 9% |
Other | 11 | 12% |
Unknown | 20 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 17% |
Biochemistry, Genetics and Molecular Biology | 16 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
Immunology and Microbiology | 8 | 9% |
Agricultural and Biological Sciences | 8 | 9% |
Other | 14 | 15% |
Unknown | 22 | 23% |